Drug Profile
Feladilimab - GSK
Alternative Names: 3359609; GSK-3359609; GSK-609Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Head and neck cancer
- Phase II Non-small cell lung cancer
- Phase I/II Multiple myeloma; Solid tumours
Most Recent Events
- 20 Jun 2023 GlaxoSmithKline terminates the phase III INDUCE-3 trial in Head and neck cancer (Combination therapy, First-line therapy, Recurrent, Metastatic disease) inin USA, United Kingdom, Australia, Argentina, Brazil, Canada, China, Denmark, France, Germany, Israel, Ireland, Italy, Japan, Greece, South Korea, Mexico, Netherlands, Portugal, Spain, Switzerland, Norway, Poland, Romania, Russia, Taiwan, Sweden, Austria and Hungary (IV) due to the sponsor's decision, based on assessment of the clinical data (NCT04128696; EudraCT2019-002263-99)
- 05 Jun 2023 GlaxoSmithKline completes a phase I trials for Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA, Australia, Canada, Italy, Netherland, Spain, China, France and Japan (IV, Infusion) (NCT02723955)
- 29 Nov 2022 Feladilimab is still in phase I trials for Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA, Australia, Canada, Italy, Netherland, Spain, China, France and Japan (IV, Infusion) (NCT02723955)